Form 4: aTyr Pharma Director Timothy Coughlin Increases Stake with $87,500 Purchase

Director Timothy Coughlin of aTyr Pharma increased his holdings by purchasing 50,000 shares of common stock at an average price of $1.75 on May 30, 2024.

Summary

• On May 30, 2024, Timothy Coughlin, a director of aTyr Pharma, acquired 50,000 shares of common stock.
• The purchase was made at an average price of $1.75 per share, totaling $87,500.
• Following the transaction, Coughlin directly owns 56,000 shares.
• Coughlin also indirectly owns shares through the Coughlin Family Trust u/a DTD 12/07/2006, where he and his spouse serve as co-trustees.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the director's stock purchase, indicating confidence. However, it's a single transaction and doesn't provide a comprehensive view of the company's overall health.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored as they can provide insights into a company's prospects. Purchases by directors are often viewed positively, suggesting confidence in the company's future performance.

Stakeholder Impact

• The stock purchase could positively influence shareholder sentiment.

Key Dates